Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 4,387,861 | 4,446,143 | 4,446,034 | 4,205,012 | 4,235,560 |
| Cost of Goods | 696,755 | 692,925 | 741,640 | 674,976 | 652,091 |
| Gross Profit | 3,691,105 | 3,753,218 | 3,704,393 | 3,530,036 | 3,583,469 |
| Operating Expenses | 1,738,000 | 1,698,978 | 2,084,153 | 1,628,060 | 1,603,771 |
| Operating Income | 1,953,860 | 2,055,165 | 1,620,880 | 1,902,952 | 1,979,789 |
| Interest Expense | 119,275 | 6,109 | -41,875 | -4,108 | 172,156 |
| Other Income | 166,345 | 197,790 | 28,069 | 61,936 | 62,267 |
| Pre-tax Income | 2,000,930 | 2,246,846 | 1,690,823 | 1,968,996 | 1,869,900 |
| Income Tax | 345,016 | 471,856 | 370,659 | 425,336 | 398,147 |
| Net Income Continuous | 1,655,914 | 1,774,990 | 1,320,164 | 1,543,660 | 1,471,753 |
| Net Income | $1,655,914 | $1,774,990 | $1,320,164 | $1,543,660 | $1,471,753 |
| EPS Basic Total Ops | 0.34 | 0.36 | 0.27 | 0.32 | 0.30 |
| EPS Basic Continuous Ops | 0.34 | 0.36 | 0.27 | 0.31 | 0.30 |
| EPS Diluted Total Ops | 0.34 | 0.36 | 0.27 | 0.32 | 0.30 |
| EPS Diluted Continuous Ops | 0.34 | 0.36 | 0.27 | 0.31 | 0.30 |
| EBITDA(a) | $2,073,157 | $2,176,018 | $1,744,461 | $2,030,367 | $2,110,613 |